Literature DB >> 18272907

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

P H Cottu, J Asselah, M Lae, J-Y Pierga, V Diéras, L Mignot, B Sigal-Zafrani, A Vincent-Salomon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18272907     DOI： 10.1093/annonc/mdn021

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  30 in total

1.  Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer.

Authors:  Julie M Wu; Marc K Halushka; Pedram Argani
Journal:  Hum Pathol       Date:  2010-03-24       Impact factor: 3.466

Review 2.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Authors:  Leticia De Mattos-Arruda; Javier Cortes; Libero Santarpia; Ana Vivancos; Josep Tabernero; Jorge S Reis-Filho; Joan Seoane
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

3.  Digital image analysis outperforms manual biomarker assessment in breast cancer.

Authors:  Gustav Stålhammar; Nelson Fuentes Martinez; Michael Lippert; Nicholas P Tobin; Ida Mølholm; Lorand Kis; Gustaf Rosin; Mattias Rantalainen; Lars Pedersen; Jonas Bergh; Michael Grunkin; Johan Hartman
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

4.  Are biopsy specimens predictive of HER2 status in gastric cancer patients?

Authors:  M Pirrelli; M L Caruso; M Di Maggio; R Armentano; A M Valentini
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

5.  Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Authors:  E Braggio; N E Kay; S VanWier; R C Tschumper; S Smoley; J E Eckel-Passow; T Sassoon; M Barrett; D L Van Dyke; J C Byrd; D F Jelinek; T D Shanafelt; R Fonseca
Journal:  Leukemia       Date:  2012-01-20       Impact factor: 11.528

6.  Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Authors:  Tamal Das; Liliane Meunier; Laurent Barbe; Diane Provencher; Olivier Guenat; Thomas Gervais; Anne-Marie Mes-Masson
Journal:  Biomicrofluidics       Date:  2013-01-10       Impact factor: 2.800

Review 7.  Heterogeneity of breast cancer: etiology and clinical relevance.

Authors:  V Almendro; G Fuster
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

8.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Authors:  M Laé; J Couturier; S Oudard; F Radvanyi; P Beuzeboc; A Vieillefond
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

9.  Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.

Authors:  Marta Kijanka; Frank-Jan Warnders; Mohamed El Khattabi; Marjolijn Lub-de Hooge; Gooitzen M van Dam; Vasilis Ntziachristos; Liesbeth de Vries; Sabrina Oliveira; Paul M P van Bergen En Henegouwen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-19       Impact factor: 9.236

Review 10.  Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

Authors:  Joan Albanell; Xavier Andreu; María José Calasanz; Angel Concha; José María Corominas; Tomás García-Caballero; José Antonio López; Fernando López-Ríos; Santiago Ramón y Cajal; Francisco J Vera-Sempere; Ramón Colomer; Miguel Martín; Emilio Alba; Antonio González-Martín; Antonio Llombart; Ana Lluch; José Palacios
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.